M. Hattersley

发表

BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non–Small Cell Lung Cancer

G. Freeman, P. Hammerman, A. Bass, 2018, Cancer Immunology Research.

Title : BET bromodomain inhibition cooperates with PD-1 blockade to facilitate antitumor 1 response in Kras-mutant non-small cell lung cancer

G. Freeman, P. Hammerman, Kwok-Kin Wong, 2018 .

Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254).

J. Janetka, A. Hird, L. Dakin, 2019, Bioorganic & medicinal chemistry.

Angiogenesis , Metastasis , and the Cellular Microenvironment Inhibition of the Hedgehog Pathway Targets the Tumor-Associated Stroma in Pancreatic Cancer

R. Hwang, Jeffrey L. Brown, T. Moore, 2012 .

Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE.

K. Stegmaier, J. Maris, G. Vassal, 2021, European journal of cancer.

Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153).

C. A. Roberts, A. Rabow, M. Waring, 2016, Journal of medicinal chemistry.

BRD4 facilitates replication stress-induced DNA damage response

G. Mills, A. Dulak, A. Lau, 2018, Oncogene.

Modelling dose and schedule effects of AZD2811 nanoparticles targeting Aurora B kinase for treatment of diffuse large B-cell lymphoma

S. Barry, S. Ashton, J. Pilling, 2019 .

A novel small-molecule IAP antagonist, AZD5582, draws Mcl-1 down-regulation for induction of apoptosis through targeting of cIAP1 and XIAP in human pancreatic cancer

E. Choi, Tae Won Kim, Seung-Woo Hong, 2015, Oncotarget.

PKC-θ-Deficient Mice Are Protected from Th1-Dependent Antigen-Induced Arthritis

M. Silva, B. Jaffee, S. Chandra, 2006, The Journal of Immunology.

A proteomic analysis of the plasma glycoproteins of a MCF-7 mouse xenograft: a model system for the detection of tumor markers.

W. Hancock, M. Hincapie, J. Hanke, 2008, Journal of proteome research.

Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3 mimetic resistance in lymphomas.

S. Fawell, L. Drew, R. Johnstone, 2020, Blood.

Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles

S. Barry, S. Ashton, Shenghua Wen, 2017, Molecular Cancer Therapeutics.

Pyridyl and thiazolyl bisamide CSF-1R inhibitors for the treatment of cancer.

David A. Scott, P. Lyne, B. Aquila, 2008, Bioorganic & medicinal chemistry letters.

BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency.

G. Mills, Z. Ju, Yiling Lu, 2018, Cancer cell.

Discovery of a novel class of dimeric Smac mimetics as potent IAP antagonists resulting in a clinical candidate for the treatment of cancer (AZD5582).

E. Hennessy, V. Oza, B. Aquila, 2013, Journal of medicinal chemistry.

Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.

S. Armstrong, M. Rivera, K. Stegmaier, 2020, European journal of cancer.

BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors

G. Mills, A. Dulak, Wei Zhao, 2018, PloS one.

The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells

Ricardo J. Miragaia, O. Delpuech, R. Miragaia, 2022, npj Precision Oncology.

The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient–Derived Xenograft Models

Rhys D O Jones, S. Cairo, S. Fawell, 2015, Clinical Cancer Research.

VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status

S. Barry, U. Cavallaro, P. Ostano, 2021, Journal of Hematology & Oncology.

Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma

S. Barry, S. Ashton, Shenghua Wen, 2019, Molecular Cancer Therapeutics.

3-amido-4-anilinoquinolines as CSF-1R kinase inhibitors 2: Optimization of the PK profile.

David A. Scott, L. Drew, L. Dakin, 2009, Bioorganic & medicinal chemistry letters.

AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies

G. Mills, A. Dulak, A. Rabow, 2016, Molecular Cancer Therapeutics.

PKC-theta-deficient mice are protected from Th1-dependent antigen-induced arthritis.

B. Jaffee, S. Chandra, D. Picarella, 2006, Journal of immunology.

Identification of CCR2 and CD180 as Robust Pharmacodynamic Tumor and Blood Biomarkers for Clinical Use with BRD4/BET Inhibitors

Greg O'Connor, J Carl Barrett, A. Dulak, 2017, Clinical Cancer Research.

First-in-human study of AZD5153, a small molecule inhibitor of bromodomain protein 4 (BRD4), in patients (pts) with relapsed/refractory (RR) malignant solid tumor and lymphoma: Preliminary data.

G. Fabbri, H. Edlund, K. Sachsenmeier, 2019, Journal of Clinical Oncology.

Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors

C. Drake, J. Bendell, D. George, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

BET inhibition targets ABC-DLBCL constitutive B-cell receptor signaling through PAX5

L. Drew, S. Criscione, D. Oien, 2023, Blood advances.

Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles

S. Barry, S. Ashton, Shenghua Wen, 2017, Molecular Cancer Therapeutics.

First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma

A. Oza, G. Fabbri, J. Saeh, 2023, Molecular cancer therapeutics.